This poster demonstrates that the use of DHAp for malaria treatment was generally safe and well tolerated. A total of 687 adverse events (AEs) were reported (0.13% of participants, 0.24% of treatments). Four AEs were initially reported as serious adverse events, though three were later identified as not related to drug ingestion.
Corporate author(s): PATH, Zambia Ministry of Health, Zambia National Malaria Elimination Centre, Tulane University
Publication date: November 2016
2,906 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
This publication is part of the series ASTMH posters
Related regions: Africa
See also: Emerging and epidemic diseases > Malaria
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA